Adell Harriman & Carpenter Inc. purchased a new stake in shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 23,029 shares of the biotechnology company’s stock, valued at approximately $141,000.

Other large investors also recently added to or reduced their stakes in the company. Amalgamated Bank boosted its stake in shares of ZIOPHARM Oncology by 12.9% during the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 1,924 shares during the period. BB&T Securities LLC purchased a new stake in shares of ZIOPHARM Oncology during the second quarter valued at approximately $112,000. Oppenheimer & Co. Inc. boosted its stake in shares of ZIOPHARM Oncology by 50.0% during the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 6,000 shares during the period. Principal Financial Group Inc. boosted its stake in shares of ZIOPHARM Oncology by 7.5% during the second quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 1,673 shares during the period. Finally, Ballentine Partners LLC purchased a new stake in shares of ZIOPHARM Oncology during the second quarter valued at approximately $162,000. 41.88% of the stock is owned by hedge funds and other institutional investors.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) traded up $0.21 during trading hours on Tuesday, hitting $4.51. The stock had a trading volume of 2,756,400 shares, compared to its average volume of 1,341,807. ZIOPHARM Oncology Inc has a 52-week low of $4.03 and a 52-week high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). The business had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. During the same period in the previous year, the business earned ($0.11) EPS. The business’s revenue was up .0% compared to the same quarter last year. sell-side analysts forecast that ZIOPHARM Oncology Inc will post -0.54 EPS for the current year.

A number of research firms have recently weighed in on ZIOP. ValuEngine lowered ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Friday. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, HC Wainwright set a $10.00 price objective on ZIOPHARM Oncology and gave the company a “buy” rating in a research note on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. ZIOPHARM Oncology currently has a consensus rating of “Hold” and a consensus price target of $12.58.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/11/14/adell-harriman-carpenter-inc-takes-position-in-ziopharm-oncology-inc-ziop.html.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper purchased 6,440 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was bought at an average price of $4.68 per share, with a total value of $30,139.20. Following the completion of the purchase, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.40% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.